Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP86260.RAIV2Ai9iWteH7iDr1EKZM-KYKHPQxOXXG8b6m7k10Vx4130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP86260.RAIV2Ai9iWteH7iDr1EKZM-KYKHPQxOXXG8b6m7k10Vx4130_assertion type Assertion NP86260.RAIV2Ai9iWteH7iDr1EKZM-KYKHPQxOXXG8b6m7k10Vx4130_head.
- NP86260.RAIV2Ai9iWteH7iDr1EKZM-KYKHPQxOXXG8b6m7k10Vx4130_assertion description "[We used the allelic discrimination method to identify polymorphisms in GSTT1, SULT1C2, CDA, SXR (drug metabolic pathways), XPD, XPA, XPG, ERCC1, TOP2A (DNA repair), VEGF (angiogenesis), and MDR1 (multidrug resistance) genes in 110 adult patients with intermediate-risk AML, enrolled in the CETLAM-99 prospective trial.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP86260.RAIV2Ai9iWteH7iDr1EKZM-KYKHPQxOXXG8b6m7k10Vx4130_provenance.
- NP86260.RAIV2Ai9iWteH7iDr1EKZM-KYKHPQxOXXG8b6m7k10Vx4130_assertion evidence source_evidence_literature NP86260.RAIV2Ai9iWteH7iDr1EKZM-KYKHPQxOXXG8b6m7k10Vx4130_provenance.
- NP86260.RAIV2Ai9iWteH7iDr1EKZM-KYKHPQxOXXG8b6m7k10Vx4130_assertion SIO_000772 16507781 NP86260.RAIV2Ai9iWteH7iDr1EKZM-KYKHPQxOXXG8b6m7k10Vx4130_provenance.
- NP86260.RAIV2Ai9iWteH7iDr1EKZM-KYKHPQxOXXG8b6m7k10Vx4130_assertion wasDerivedFrom gad-20150221 NP86260.RAIV2Ai9iWteH7iDr1EKZM-KYKHPQxOXXG8b6m7k10Vx4130_provenance.
- NP86260.RAIV2Ai9iWteH7iDr1EKZM-KYKHPQxOXXG8b6m7k10Vx4130_assertion wasGeneratedBy ECO_0000203 NP86260.RAIV2Ai9iWteH7iDr1EKZM-KYKHPQxOXXG8b6m7k10Vx4130_provenance.